Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649385 · ClinicalTrials.gov registry record · Phase 1
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by BeiGene.
- Active
- Registry status
- Phase 1
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT04649385: Active Phase 1 study of Advanced Solid Tumor, sponsored by BeiGene.
NCT04649385 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 157 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04649385, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.
Primary Outcome
Participants will be considered evaluable for DLTs if they 1) received ≥ 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG BGB-15025
Study Locations (20)
Seoul Teugbyeolsi
- Samsung Medical Center - GangnamGu
- The Catholic University of Korea, Seoul St Marys Hospital - SeochoGu
- Severance Hospital Yonsei University Health System - SeodaemunGu
- Asan Medical Center - SongpaGu
Texas
- The University of Texas Md Anderson Cancer Center - Houston
- Ut Health San Antonio Mays Cancer Center - San Antonio
Henan
- Henan Cancer Hospital - Zhengzhou
- The First Affiliated Hospital of Zhengzhou University - Zhengzhou
New York
- Icahn School of Medicine At Mount Sinai - New York
New South Wales
- Prince of Wales Hospital - Randwick
South Australia
- Ashford Cancer Centre Research Northeast - Windsor Gardens
Victoria
- Peter Maccallum Cancer Centre - Melbourne
Western Australia
- Linear Clinical Research - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2026-05-16 |
| Phase | Phase 1 |
What the registry record for NCT04649385 still lists
NCT04649385 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Tislelizumab is the first listed.
NCT04649385 names 20 study sites across 15 states, led by Seoul Teugbyeolsi, Texas, Henan.
Frequently Asked Questions
What is clinical trial NCT04649385 about?
NCT04649385 is a clinical study titled "BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors". The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with t...
What is the current status of trial NCT04649385?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2021-03-04. Estimated completion is 2026-05-16.
What conditions does trial NCT04649385 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT04649385?
The interventions under investigation include: Tislelizumab (DRUG), BGB-15025 (DRUG).
Who is sponsoring clinical trial NCT04649385?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04649385 being conducted?
This trial has 20 study locations across New York, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04649385's enrollment target sits among peer trials
157 81st of 189 higher than 109 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI